Literature DB >> 28105175

Analysis of transcription profile to reveal altered signaling pathways following the overexpression of human desumoylating isopeptidase 2 in pancreatic cancer cells.

Yu-Yin Fu1, Yu-Huan Kang1, Cong-Cong Shen1, Rui-Xue Wang1, Lin Yu1, Xin-Yue Li1, Dan-Dan Cui2, Jin-Liang Yang1, Yu-Qin Yao3, Lan-Tu Gou1.   

Abstract

Human desumoylating isopeptidase 2 (DESI-2) is a member of the DESI family and contains a conserved PPPDE1 domain. Previous studies have demonstrated that DESI-2 overexpression may induce cell apoptosis. In the present study, differentially expressed genes were analyzed using a transcription microarray in DESI-2 overexpressing PANC-1 pancreatic cancer cells. A total of 45,033 genes were examined by microarray, which identified 1,766 upregulated and 1,643 downregulated genes. A series of altered signaling pathways were analyzed, in which certain essential signaling factors, including retinoid X receptor (RXR), BH3 interacting-domain death agonist, Ras homolog gene family member A (RhoA) and Rho-associated protein kinase, were further investigated at the protein level. The release of cytochrome c and the activation of caspase-3 were also detected by western blot analysis. Immunohistochemistry further revealed the expression features of RXR and RhoA in pancreatic ductal adenocarcinoma tissues with various DESI-2 expression levels. The results serve as a valuable reference for the further elucidation of the functions of DESI-2 in pancreatic cancer.

Entities:  

Keywords:  human desumoylating isopeptidase 2; immunohistochemistry; microarray; pancreatic cancer; signaling pathway

Year:  2016        PMID: 28105175      PMCID: PMC5228388          DOI: 10.3892/ol.2016.5298

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

Review 1.  SUMOylation code in cancer development and metastasis.

Authors:  Keun Il Kim; Sung Hee Baek
Journal:  Mol Cells       Date:  2006-12-31       Impact factor: 5.034

Review 2.  Concepts in sumoylation: a decade on.

Authors:  Ruth Geiss-Friedlander; Frauke Melchior
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

3.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

4.  Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma.

Authors:  Lantu Gou; Wei Wang; Aiping Tong; Yuqin Yao; Yan Zhou; Cheng Yi; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2011-04-08       Impact factor: 4.599

5.  RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones.

Authors:  Marco Della Peruta; Cinzia Giagulli; Carlo Laudanna; Aldo Scarpa; Claudio Sorio
Journal:  Mol Cancer       Date:  2010-03-17       Impact factor: 27.401

6.  In vivo activation of PPAR target genes by RXR homodimers.

Authors:  Annemieke IJpenberg; Nguan Soon Tan; Laurent Gelman; Sander Kersten; Josiane Seydoux; Jianming Xu; Daniel Metzger; Laurence Canaple; Pierre Chambon; Walter Wahli; Béatrice Desvergne
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

7.  A novel pro-apoptosis gene PNAS4 that induces apoptosis in A549 human lung adenocarcinoma cells and inhibits tumor growth in mice.

Authors:  Fei Yan; Lantu Gou; Jinliang Yang; Lijuan Chen; Aiping Tong; Minghai Tang; Zhu Yuan; Shaohua Yao; Peng Zhang; Yuquan Wei
Journal:  Biochimie       Date:  2008-12-24       Impact factor: 4.079

8.  Comprehensive analysis of expression profile reveals the ubiquitous distribution of PPPDE peptidase domain 1, a Golgi apparatus component, and its implications in clinical cancer.

Authors:  Yi He; Jiangman Wang; Lantu Gou; Congcong Shen; Liangyin Chen; Cheng Yi; Xian Wei; Jinliang Yang
Journal:  Biochimie       Date:  2013-04-06       Impact factor: 4.079

9.  Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.

Authors:  Tinghua Hu; Hui Guo; Wenjuan Wang; Shuo Yu; Lili Han; Lili Jiang; Jiequn Ma; Chengcheng Yang; Qianqian Guo; Kejun Nan
Journal:  Oncol Rep       Date:  2013-07-09       Impact factor: 3.906

10.  Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management.

Authors:  Kenji Yamazaki; Masahito Shimizu; Masataka Okuno; Rie Matsushima-Nishiwaki; Nobuhiro Kanemura; Hiroshi Araki; Hisashi Tsurumi; Soichi Kojima; I Bernard Weinstein; Hisataka Moriwaki
Journal:  Gut       Date:  2007-06-29       Impact factor: 23.059

View more
  2 in total

1.  A previously unknown Argonaute 2 variant positively modulates the viability of melanoma cells.

Authors:  Lisa Linck-Paulus; Tina Meißgeier; Katharina Pieger; Anselm H C Horn; Alexander Matthies; Stefan Fischer; Gunter Meister; Heinrich Sticht; Melanie Kappelmann-Fenzl; Anja K Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2022-08-09       Impact factor: 9.207

2.  LINC00472 suppressed by ZEB1 regulates the miR-23a-3p/FOXO3/BID axis to inhibit the progression of pancreatic cancer.

Authors:  Cong Bi; Gang Wang
Journal:  J Cell Mol Med       Date:  2021-08-07       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.